This provider-led peer review will focus on navigating post-operative complications in cataract surgery. While the risk of complications is low, understanding how to assess, diagnose, and manage them is essential for optometrists involved in post-operative care. This session will provide...
Researchers identify a novel genetic cause of Fuchs endothelial corneal dystrophy, offering new ways for future therapies to target this common, age-related cause of visual loss. In a landmark study, researchers supported by NIHR Moorfields Biomedical Research Centre, have identified...
Modern cataract surgery aims to provide patients with the best possible visual outcome with the least dependence on spectacles and minimal or no complications and to treat both cataract and refractive errors with a single procedure. Phacoemulsification is the standard...
The early 1980s were a glorious time to be a teenager. Along with BMX bikes, Airwolf and Quattro, we had a plethora of new music genres to be enthralled by. The band Frankie Goes to Hollywood with their dance /...
TED seriesNational meeting series on thyroid eye diseaseThe Adnexal Team at Moorfields Eye Hospital are pleased to present TED series, an ongoing series of FREE, evening hybrid meetings covering key aspects of thyroid eye disease. The aim of the meetings...
It is well known that multifocal intraocular lenses (IOLs) can generate more than one focus to restore distance and near vision, but patients may experience adverse optical phenomena such as decreased contrast sensitivity and induced glare or halos. The authors...
Staffing shortages, financial constraints, and an ongoing rise in demand: none of these factors remove the need for high-quality healthcare, yet combined they threaten its realisation.
This article discusses the use of topical and systemic therapy in the management of advanced periocular tumours. It focuses on those that have gained United States Food and Drug Administration approval; namely imiquimod, vismodegib, sonidegib, pembrolizumab and cemiplimab. Imiquimod is...
3 February 2023
| Yarrow Scantling-Birch, Zaria Ali
|
EYE - General
Ophthalmology specialist training (OST) is a fantastic career option, however, it is also a highly competitive specialty. There was a gradual rise in competition ratios in recent years: 3.24 (2019), 5.73 (2020), and 6.80 (2021) [1]. Many choose to pursue...
3 February 2023
| Yarrow Scantling-Birch, Zaria Ali
|
EYE - General
Ophthalmology specialist training (OST) is a fantastic career option, however, it is also a highly competitive specialty. There was a gradual rise in competition ratios in recent years: 3.24 (2019), 5.73 (2020), and 6.80 (2021) [1]. Many choose to pursue...